RETIRED: The use of magnetic resonance imaging in the obstetric patient.

This document has been archived because it contains outdated information. It should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines.

Ce document a été archivé, car il contient des informations périmées. Il ne devrait pas être consulté pour un usage clinique, mais uniquement pour des recherches historiques. Veuillez consulter le site web du journal pour les directives les plus récentes.

Detection and differential diagnosis of suspected malignant transformation of an endometrioma during pregnancy.

Asymptomatic female in her early 30s presented for her singleton nuchal translucency ultrasound at 12.4 weeks of gestational age. No fetal abnormalities were seen. A large maternal left adnexal mass was identified, prompting a transvaginal ultrasound. The findings were felt to be consistent with an endometrioma, albeit with a 1 cm solid nodule. At this point, the diagnosis was considered to likely represent a decidualised endometrioma; however, warranting careful follow-up. The 20-week anatomy scan demonstrated an enlarging solid nodule that now contained vascularity within the left adnexal mass prompting an MRI. These features were more suggestive of malignancy, although a decidualised endometrioma, which can demonstrate intrapartum growth and vascularity, remained in the differential. Intrapartum sonographic surveillance documented progressive growth. The lesion was uneventfully removed at the time of delivery. Pathology showed clear cell carcinoma within an endometrioma.

SOGC CLINICAL PRACTICE GUIDELINE: guidelines for the management of vasa previa.

OBJECTIVES: To describe the etiology of vasa previa and the risk factors and associated condition, to identify the various clinical presentations of vasa previa, to describe the ultrasound tools used in its diagnosis, and to describe the management of vasa previa. OUTCOMES: Reduction of perinatal mortality, short-term neonatal morbidity, long-term infant morbidity, and short-term and long-term maternal morbidity and mortality. EVIDENCE: Published literature on randomized trials prospective cohort studies, and selected retrospective cohort studies was retrieved through searches of PubMed or Medline, CINAHL, and the Cochrane Library, using appropriate controlled vocabulary (e.g., selected epidemiological studies comparing delivery by Caesarean section with vaginal delivery studies comparing outcomes when vasa previa is diagnosed antenatally vs.intrapartum) and key words (e.g. vasa previa). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Searches were updated on a regular basis and incorporated into the guideline to October 1, 2008. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies,clinical practice guideline collections, clinical trial registries, and from national and international medical specialty societies. VALUES: The evidence collected was reviewed by the Diagnostic Imaging Committee and the Maternal Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and quantified using the evaluation of evidence guidelines developed by the Canadian Task Force on Preventive Health Care. BENEFITS, HARMS, AND COSTS: The benefit expected from this guideline is facilitation of optimal and uniform care for pregnancies complicated by vasa previa. SPONSORS: The Society of Obstetricians and Gynaecologists of Canada.

Initial evaluation and referral guidelines for management of pelvic/ovarian masses.

OBJECTIVES: To optimize the management of adnexal masses and to assist primary care physicians and gynaecologists determine which patients presenting with an ovarian mass with a significant risk of malignancy should be considered for gynaecologic oncology referral and management. OPTIONS: Laparoscopic evaluation, comprehensive surgical staging for early ovarian cancer, or tumour debulking for advanced stage ovarian cancer. OUTCOMES: To optimize conservative versus operative management of women with possible ovarian malignancy and to optimize the involvement of gynaecologic oncologists in planning and delivery of treatment. EVIDENCE: Published literature was retrieved through searches of PubMed or MEDLINE, CINAHL, and the Cochrane Library, using appropriate controlled vocabulary and key words. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Grey (unpublished) literature was identified by searching the web sites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. RECOMMENDATIONS: 1. Primary care physicians and gynaecologists should always consider the possibility of an underlying ovarian cancer in patients in any age group who present with an adnexal or ovarian mass. (II-2B) 2. Appropriate workup of a perimenopausal or postmenopausal woman presenting with an adnexal mass should include evaluation of symptoms and signs suggestive of malignancy, such as persistent pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, and difficulty eating. In addition, CA125 measurement should be considered. (II-2B) 3. Transvaginal or transabdominal ultrasound examination is recommended as part of the initial workup of a complex adnexal/ovarian mass. (II-2B) 4. Ultrasound reports should be standardized to include size and unilateral/bilateral location of the adnexal mass and its possible origin, thickness of septations, presence of excrescences and internal solid components, vascular flow distribution pattern, and presence or absence of ascites. This information is essential for calculating the risk of malignancy index II score to identify pelvic mass with high malignant potential. (IIIC) 5. Patients deemed to have a high risk of an underlying malignancy should be reviewed in consultation with a gynaecologic oncologist for assessment and optimal surgical management. (II-2B).

Adnexal masses in the pregnant patient: a diagnostic and management challenge.

Ultrasound is a valuable diagnostic tool, which can be used to stratify pregnant women with adnexal masses into a conservative management protocol versus those that require further diagnostic and management decisions. Familiarity with the natural history and sonographic features of common adnexal lesions, such as simple cysts, hemorrhagic cysts, endometriomas, mature cystic teratomas, and ovarian conditions specific to pregnancy, may permit stratification of patients into management protocols. The goal of ultrasound evaluation in the pregnant patient with an adnexal mass is to identify those patients in whom conservative management is appropriate versus those who require more immediate interventions such as surgery. The risk of surgical interventions needs to be balanced against the potential risks of nonintervention, which may include torsion, rupture, hemorrhage, or the rare spread of a malignant cancer. Atypical features or persistent large lesions should initiate a multidisciplinary team approach to optimize diagnostic and management strategy. Acute symptoms may precipitate emergency intervention at any point in the pregnancy. We will present a diagnostic and management algorithm based on clinical symptoms, timing of detection, natural history, and sonographic features of adnexal masses in pregnancy.

The prevalence of incidental simple ovarian cysts >or= 3 cm detected by transvaginal sonography in early pregnancy.

OBJECTIVE: To determine the prevalence of simple ovarian cysts of >or= 3 cm diameter detected by transvaginal sonography (TVS) in a population of asymptomatic women in early pregnancy. METHODS: We conducted a retrospective review of 10,830 consecutive women presenting prior to 14 weeks' gestational age (GA) for early dating TVS. The records of all women with simple cysts >or= 3 cm in diameter were included. The study population was divided into five groups by GA: >or= 6 weeks; 6.1-8 weeks; 8.1-10 weeks; 10.1-12 weeks; and 12.1-14 weeks. RESULTS: A simple cyst >or= 3 cm in diameter was present in 4.9% of women at >or= 6 weeks' gestation, in 5.1% between 6.1 and 8 weeks, in 5.3% between 8.1 and 10 weeks, in 3.2% between 10.1. and 12 weeks, and in 1.5% between 12 and 14 weeks. Overall, a simple cyst >or= 3 cm was present in 516 women (4.8%). Prior to 10 weeks, 5.1% had simple cysts >or= 3 cm, dropping to 2.7% after 10 weeks, a statistically significant decrease (P<0.0001). Between 10.1 weeks and 12 weeks, the prevalence dropped to 3.2%, and then to 1.5% in the 12.1-14 week group. CONCLUSION: This investigation provides reference data on the prevalence of detecting simple ovarian cysts >or= 3 cm by TVS in an asymptomatic early pregnancy population. A progressive decline in the frequency of detecting simple ovarian cysts >or= 3 cm begins after 10 weeks' gestational age.

Visualization of the ovaries in early pregnancy by transvaginal sonography.

OBJECTIVE: To determine the frequency of visualization of the ovaries by transvaginal sonography (TVS) in a group of women in early pregnancy and to determine the onset of a decrease in sonographic visualization of the ovaries during this time. METHODS: The study population included all patients with an intrauterine pregnancy confirmed by the presence of a yolk sac,embryo, or fetus. The biometric data included crown-rump length and/or gestational sac mean diameter corresponding to < - 14 weeks' gestational age (GA). RESULTS: The study population included 11,095 women, of whom 1972 (17.8%) had a GA < - 6 weeks, 4665 (42.0%) 6.1 to 8 weeks, 2782 (25.1%) 8.1 to 10 weeks, 1208 (10.1%) 10.1 to 12 weeks, and 468 (4.2%) 12.1 to 14 weeks. At least one ovary was identified in 11,043 women (99.5%), and both ovaries were identified in 10,620 women (95.7%). Only the right ovary was identified in 274 women (2.5%), and only the left ovary was identified in 149 women (1.3%). In 52 women (0.5%), neither ovary was identified. Both ovaries were identified in 1929 pregnancies of < - 6 weeks' GA (97.8%), in 4528 between 6.1 and 8 weeks' GA (97.1%), in 2664 between 8.1 and 10 weeks, GA (95.8%), in 1114 between 10.1 and 12 weeks' GA (92.2%), and in 385 between 12.1 and 14 weeks' GA (82.3%). CONCLUSION: Transvaginal sonography achieved an overall visualization of one or both ovaries in 99.5% women with pregnancies of < - 14 weeks, GA. Both ovaries were visualized in 95.7% of women. A significant decline in ovarian visualization occurred after 10 weeks' GA. The results provide reference data on the likelihood of ovarian visualization in early pregnancy.

A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study.

BACKGROUND: Mechanical and infectious complications shorten the effective duration of peripherally inserted central venous catheters. Heparin use to prevent such complications and prolong the usability of peripherally inserted central venous catheters is inconclusive. OBJECTIVE: Our goal was to evaluate the effectiveness of heparin in prolonging the usability of peripherally inserted central venous catheters in neonates. DESIGN/METHODS: We performed a multicenter, randomized, controlled trial of heparin infusion (0.5 U/kg per hour) versus placebo for peripherally inserted central venous catheters in neonates. The primary outcome was duration of catheter use. Secondary outcomes were occlusion, catheter-related sepsis, thrombosis, and adverse effects of heparin. To detect a 168-hour (1-week) difference in the duration of catheter use, 192 patients were needed. Kaplan-Meier and Cox regression analyses were performed. RESULTS: A total of 201 neonates were enrolled (heparin group: n = 100; control group: n = 101). Baseline demographics were similar between the groups. Duration of catheter use was longer in the infants in the heparin versus the placebo group. Study center, gender, birth weight, and type and position of the catheter were not predictors of duration of catheter use. For those in the heparin versus the placebo group, the incidence of elective catheter removal (therapy completed) was 63% vs 42%, of occlusion was 6% vs 31%, of thrombosis was 20% vs 21%, and of catheter-related sepsis was 10% vs 6%, respectively. No adverse events were noted. CONCLUSIONS: Heparin infusion prolonged the duration of peripherally inserted central venous catheter usability, which permitted a higher percentage of neonates to complete therapy without increasing adverse effects.

Detection of fetal structural abnormalities with US during early pregnancy.

Ultrasonography (US) is performed during early pregnancy for dating, determination of the number of fetuses, assessment of early complications, and increasingly for evaluation of the fetus, including measurement of the thickness of the nuchal translucency (NT). Measurement of NT thickness between 11 and 14 weeks gestation, combined with maternal age and maternal serum biochemistry, can be an effective method of screening for trisomy 21 and other chromosomal abnormalities. Furthermore, an increased NT thickness in the presence of a normal karyotype is associated with an increased frequency of structural defects and genetic syndromes. Therefore, this finding is an indication for a more detailed anatomic survey of the fetus. Besides nuchal abnormalities, a wide range of other congenital anomalies can be diagnosed with US at 11-14 weeks gestation, including defects of the central nervous system, heart, anterior abdominal wall, urinary tract, and skeleton. The anatomic survey can be performed with a standardized protocol by using transabdominal US and, when necessary, transvaginal US. A thorough knowledge of the US features of normal fetal development is necessary to avoid potential diagnostic pitfalls.

RETIRED: The use of first trimester ultrasound.

This document has been archived because it contains outdated information. It should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines.